In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)," the substance sold as TB-500, on Category 2 of its interim 503A bulk drug substances list, meaning FDA identified significant safety concerns and would not permit licensed compounding pharmacies to use it
However, in a recent study on the inhibition of Hepa1-6 cell proliferation induced by oxidative stress, we found that increased expression of GPX6 protein may play a role in inhibiting oxidative stress (Tan et al., 2022)
To illustrate, these toxins included industrial chemicals, heavy metals, polychlorinated biphenyls (PCBs), insecticides, dioxin, and benzene
However, major expert groups have looked at the research and concluded that: The evidence is not sufficient to show that screening every adult without symptoms for vitamin D deficiency clearly improves outcomes such as fractures, heart disease or cancer